Quick answer: Buyers of a supplement company test whether the product record creates liability they would inherit and whether profit survives the full cost of keeping customers. They trace sampled lots from ingredient to customer, trace live claims to their support, tie marketplace payouts to the bank, and rebuild subscription cohorts and refund reserves from order data. Past exposures reduce price or draw indemnities, while higher run-rate costs lower adjusted EBITDA and, through the multiple, price.
Key points
- A buyer’s quality specialist traces sampled lots from ingredient to customer, and a broken trace points to a broad, slow recall and to corrective conditions before closing.
- Counsel traces each live claim to the support held for it, including claims made on the company’s behalf by affiliates and influencers.
- Accountants rebuild subscription cohorts and refund reserves from order-level data, so retention and refund rates reported on a dashboard are not taken at face value.
- Past exposures are deducted from price or covered by indemnity, while corrected run-rate costs lower adjusted EBITDA and are scaled up by the multiple.
What a buyer decides in supplement diligence
A buyer of a supplement company settles two questions, and different people answer them. The first is whether the product record creates liability the buyer inherits: what the company made, what it said about the product and what it did when something went wrong. A quality specialist and regulatory counsel work on it, and the answers set deductions, indemnities and closing conditions. The second is whether profit would survive the full cost of winning and keeping customers. Accountants answer that one, and the result sets adjusted EBITDA.
Under DSHEA, manufacturers and distributors are responsible for evaluating the safety and labeling of their products before marketing, and FDA can act against adulterated or misbranded supplements after they reach the market.[1] The company’s own records are therefore the evidence, which is why the first requests ask for them. Multiples and value drivers are in the valuation page for supplement companies, and the directory of diligence by industry compares other businesses.
Tracing a lot from ingredient to customer
FDA’s current good manufacturing practice rule for dietary supplements applies to anyone who manufactures, packages, labels or holds a supplement, and it covers personnel, the plant and equipment, production and process controls with quality control and batch production records, holding and distributing, returned products, product complaints and records.[2] The buyer’s quality specialist turns that list into a test.
The specialist picks finished lots from different months and products, then follows each one through the batch production record, the ingredient lots and their certificates of analysis, the finished-product test result, any out-of-specification result and how it was closed, and the shipments that reached customers. The trace breaks when a record is missing, a result was never investigated or a lot cannot be tied to the customers who received it. A broken trace suggests that a recall would be broad and slow, and it can lead to corrective-action conditions before closing, a specific indemnity or a lower price.
For a brand that outsources production, the same trace runs through the contract manufacturer. The buyer reads the quality agreement and the manufacturer’s audit reports to see who keeps which records, and asks to speak with the manufacturer. Supplier files get matching treatment: the approved supplier list, qualification records and the ingredients that have only one source. Complaint and returned-product logs are read for patterns by lot rather than only counted, and insurance policies and loss runs are read beside the results, since product liability and recall coverage are the buyer’s backstop for what the trace cannot rule out.
Tracing a claim from the page to its support
Counsel starts from what is live: a label, a marketplace listing, a landing page, a paid ad, an email or a creator post. For each claim the company is asked for the support behind it. FTC guidance says advertisers need adequate substantiation for objective product claims before an ad runs, that claims about health benefits or safety generally require competent and reliable scientific evidence, that anyone who participates in marketing can be liable, and that a DSHEA disclaimer does not cure an otherwise deceptive ad.[3]
- Claim to support. Each claim is matched to a study, an ingredient dossier or supplier data, with a date and a named reviewer. Claims that outrun their support, or support that covers a different dose or form than the product sells, are listed.
- Creators and affiliates. Counsel reads the agreements, the talking points supplied, approval rights and takedown steps, because what these partners say is the company’s exposure.
- Outside letters. Platform notices, regulator letters, competitor challenges and consumer demands are read with the response and the date each was closed.
A claim with no support is not automatically fatal. The company can produce support it holds, change the copy, or accept protection for the buyer. Where the claim drives sales, accountants test how much revenue depends on it, because a product that must be reformulated or withdrawn lowers the earnings base instead of creating a single cost.
Tracing marketplace payouts to the bank
Sales through a marketplace are tested like any other revenue, with one difference: the platform reports sales, fees, refunds and reserves in its settlement reports, and cash reaches the bank net of all of them. The accountants tie settlement reports to ledger revenue and to bank deposits and list every unmatched item, as described in proof of cash. Unmatched items mark where revenue was booked before cash arrived, fees were netted or refunds were recorded late.
Account standing is the second test. The buyer asks for the history of suspensions, listing removals and policy notices, who controls the brand registration and the listings, and how much profit is exposed if the account were restricted. Payment processors can also hold reserves against refunds and disputes, so the buyer asks for processor statements and any hold notices, since a held balance is cash it cannot count on at closing. Advertising accounts are checked the same way, with spend by platform tied to marketing expense in the ledger.
Rebuilding subscription cohorts, refunds and chargebacks
A dashboard shows retention the way the company defines it. Accountants rebuild cohorts from order-level data: who started in which month, on which offer, how many shipments they received and when they stopped. They tie subscription billings to the ledger, then separate customers recruited with introductory pricing from those who started at the full price, because retention often differs between the two. Revenue billed in advance for prepaid plans is tested under revenue recognition in diligence.
Refunds and chargebacks get a look-back test. The reserve at period end is compared with the refunds and disputes actually processed in the weeks after, and a reserve below the look-back rate lowers adjusted EBITDA by the difference. A rising dispute rate also draws questions about how offers were presented. Retention that does not survive the rebuild lowers recurring revenue and often moves price into an earnout, as discussed in revenue quality and recurring revenue.
Adjustments to supplement earnings
The method is laid out in normalizing earnings for a sale, and the challenge process in how buyers challenge add-backs. These adjustments most often move a supplement company’s earnings in a buyer’s review.
| Adjustment | Why buyers question it | Support they expect |
|---|---|---|
| Refund and chargeback reserve restated to the look-back rate (lowers EBITDA) | Reserves are often set by habit and trail actual disputes | Refund and dispute data by month, processor statements |
| Growth marketing added back | Spend that holds revenue in place is a cost of the business, and only spend that buys new customers can be argued as discretionary | Cohort payback by channel, results when spending paused |
| Near-dated and expired stock written down (lowers EBITDA) | Finished goods carry best-by dates, and write-offs often come late | Inventory aging by lot, write-off history, sales velocity |
| Retesting, relabeling and recall costs added back | Accepted only if the cause is fixed, since repeated lot failures are an operating cost | Root-cause reports, corrective-action records, prior-year costs |
| Legal and settlement costs on claims disputes added back | Accepted only if the practice behind the dispute has changed | Settlement agreements, revised copy, approval records |
| Affiliate and creator commissions accrued (lowers EBITDA) | Unrecorded commissions and free product understate marketing | Agreements, payout reports, accrual roll-forward |
| Manufacturer or ingredient price increases not yet in the numbers (lowers EBITDA) | Current costs may exceed the average for the period | Supplier quotes, purchase orders, price-change notices |
| Owner pay and personal expenses | Added back only down to a market replacement cost | Market pay data, expense detail |
Illustrative example: How a look-back test and a claims settlement reach price
An owner presents adjusted EBITDA of $2,400,000, and a buyer applies a placeholder multiple of 6.0x, for a price of $14,400,000. Subscription revenue is $15,000,000, and the refund reserve is set at 3.0 percent of it. The buyer’s review makes three findings.
| Finding | Where it lands | Effect on price |
|---|---|---|
| Refunds and chargebacks processed after period end imply 4.0 percent, so the reserve is short by 1.0 percent of $15,000,000, or $150,000 a year | Adjusted EBITDA | $900,000 |
| Of $200,000 of retesting and relabeling added back as one-time, $100,000 also appears in the prior year and is rejected | Adjusted EBITDA | $600,000 |
| A $250,000 settlement of a claims dispute, excluded from the owner’s EBITDA as one-time, is agreed but unpaid at closing | Debt-like item | $250,000 |
Adjusted EBITDA falls by $250,000 to $2,150,000, which at 6.0x is $12,900,000, and the unpaid settlement takes the price to $12,650,000, a reduction of $1,750,000. The settlement is not an EBITDA item because it is a bill for the past, while the reserve and the retesting costs measure what the business costs to run. The numbers are invented to show the mechanics and are not benchmarks.
Structure when the product record is unclear
When a trace breaks or a claim cannot be supported, a buyer has several tools: a specific indemnity or escrow for the named issue, a closing condition that the company correct its copy or its records, a lower price for the earnings base, or an earnout on the channel or product at risk. How the first two work is covered in representations, warranties, indemnification and escrows. The tool chosen usually depends on whether the problem can be measured. A defined list of lots or claims can be priced or indemnified, and open-ended uncertainty is more likely to become an escrow or an earnout.
An owner can run these traces first, and a sell-side quality of earnings report covers the financial side independently. The results feed the process in how to sell a supplement business, while a buyer’s screen of the same issues is in buying a dietary supplement business. The Impetus Group offers fractional investment banking support, including earnings normalization, CIM preparation and diligence navigation, for owners who want these tests run before buyers arrive.
Frequently asked questions
What documents does a buyer request first from a supplement company?
Order-level sales data by channel, marketplace settlement reports and bank statements, cohort and refund data, batch records and certificates of analysis for sampled lots, supplier lists, the manufacturing and quality agreements, a list of every claim in use with its support, complaint logs, insurance policies and loss runs. Together they test earnings, quality and claims.
Is a product recall treated as an add-back for a supplement company?
Sometimes, and in part. A recall or retest cost is accepted as one-time only if the cause is found and fixed, and the buyer checks earlier years for similar costs. Insurance recoveries, lost sales and replacement product are separated, and an unpaid recall obligation at closing may be treated as a debt-like item.
How do buyers test subscription revenue at a supplement brand?
They rebuild cohorts from order-level data instead of relying on a dashboard, then tie subscription billing to the ledger and the bank. They separate introductory offers from full-price orders, test skips and cancellations, and compare the refund reserve with refunds actually processed after period end. Retention that fails the rebuild lowers recurring revenue and often moves price into an earnout.
Does a supplement buyer review the contract manufacturer too?
Often, yes. A buyer reads the manufacturing and quality agreements, asks for audit reports, and may want to speak with the manufacturer or inspect its plant. It checks who owns the formula, whether the agreement survives a change of control and what minimum volumes and price changes are built in. Timing is agreed with the seller, because the manufacturer must be told.
What happens in diligence if a claim on the label has no support?
The buyer’s counsel flags it, and the company can produce support it holds, change the claim, or accept protection for the buyer, such as a specific indemnity or escrow. Where the claim drives sales, accountants also test how much revenue depends on it, since a product that must be reformulated or withdrawn lowers the earnings base.
Preparing a company for sale or a buyer's diligence?
The Impetus Group offers fractional investment banking support, including earnings normalization, financial projections, CIM preparation and help navigating buyer diligence, with an engagement scoped to what the business needs.
Related guides
- Nutritional supplement manufacturers: How buyers value supplement brands and contract manufacturers: repeat revenue, marketing efficiency, platform risk, compliance, ingredient sourcing and multiples.
- How to Sell a Supplement Business: Compliance Files, Channels and Buyer Types: How to sell a supplement business: buyer types, the claims and manufacturing files to prepare, channel evidence, and how deal structure handles open risk.
- Buying a Supplement Company: Regulatory Risk, Suppliers, Channels and Deal Structure: Buying a supplement company: the screens to run before bidding on regulatory exposure, manufacturer and supplier dependence, channels and customer economics.
- Beauty and Personal Care Brand Due Diligence: Returns, Retailer Terms and Margins: What buyers test in beauty brand due diligence: gross-to-net and returns, retailer terms, inventory reserves, marketing spend, formula files and add-backs.
- Accounting Firm Due Diligence: Client Roster, Partner Pay and Normalized Earnings: Accounting firm due diligence: how buyers test the client roster, retention, work in process, partner pay, quality-control records and staff before they set price.
- Engineering Firm Due Diligence: Utilization, Work in Process and Adjusted EBITDA: Engineering firm due diligence: how buyers test utilization, the multiplier, work in process, fixed-fee margin fade, contracts, insurance and principal pay.
Sources
- Dietary supplements. U.S. Food and Drug Administration. Accessed October 13, 2026.
- Small entity compliance guide: current good manufacturing practice in manufacturing, packaging, labeling, or holding operations for dietary supplements. U.S. Food and Drug Administration, Human Foods Program. Accessed October 13, 2026.
- Health products compliance guidance. Federal Trade Commission. Accessed October 13, 2026.
This guide is general education. It is not a valuation opinion, appraisal, investment advice, or legal or tax advice. How these guides are made.